MXCT — MAXCYTE, INC.

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1287098 ·
Last close
$1.00
Market Cap
$107.12M
52W High
$1.16
52W Low
$0.66
ADV30
964,197
Next earnings
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 9,651,000 8,082,000 -6,185,000 -4,750,000 194,473,000 14,557,000 26,587,000
Dec 2025 7,300,000 5,690,000 -7,672,000 -9,596,000 202,507,000 20,065,000 31,017,000
Sep 2025 6,829,000 5,233,000 -11,091,000 -12,416,000 213,476,000 12,973,000 33,201,000
Jun 2025 8,507,000 6,988,000 -14,227,000 -12,357,000 219,750,000 15,225,000 29,027,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-34,410,000
Investing CF
$25,935,000
Financing CF
$656,000
CapEx
$-1,768,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.43
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-261,483,000
Inventory
$7,547,000
Receivables
$3,503,000
ST Investments
$82,979,000
EBIT TTM
$-45,285,000
Pretax Income TTM
$-44,630,000
Interest Exp TTM
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,287,000
EBITDA
$-34,161,000
Free Cash Flow
$-14,128,000
Enterprise Value
$22,039,538
Total Cash
$106,854,000
Total Debt
$17,487,000
Shares Out
107,121,672
Trailing EPS
$-0.37
Book Value
$1.57
ROE
-21.3%
ROA
-11.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 33,026,000 -45,285,000 -44,630,000 202,507,000 31,017,000 -34,410,000
Dec 2024 38,627,000 -51,197,000 -41,055,000 239,470,000 33,219,000 -27,610,000
Dec 2023 41,288,000 -48,299,000 -37,923,000 268,274,000 36,107,000 -21,686,000
Dec 2022 44,261,000 -27,361,000 -23,571,000 286,653,000 32,685,000 -14,783,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.25

Peers — same industry

TickerNameMarket CapLastDaily %
ICCC IMMUCELL CORP /DE/ $94.99M $10.50
IMDX Insight Molecular Diagnostics Inc. $207.95M $6.44
TKNO Alpha Teknova, Inc. $213.92M $3.99
ONMD OneMedNet Corp $48.17M $0.88
MYGN MYRIAD GENETICS INC $363.63M $3.85

News headlines (Yahoo Finance, 1h cache)

12 Health Care Stocks Moving In Wednesday's Intraday Session
2026-05-13 17:06 · Yahoo
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors
2026-05-13 09:27 · Yahoo
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
2026-05-13 08:14 · Yahoo
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...
2026-05-13 05:01 · Yahoo
MaxCyte Q1 Earnings Call Highlights
2026-05-13 01:09 · Yahoo
MaxCyte, Inc. Q1 2026 Earnings Call Summary
2026-05-13 00:53 · Yahoo
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:40 · Yahoo
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
2026-05-12 20:05 · Yahoo
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
2026-04-29 20:05 · Yahoo
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-31 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.